Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Berend Jan Bosch is active.

Publication


Featured researches published by Berend Jan Bosch.


Nature | 2013

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

V. Stalin Raj; Huihui Mou; Saskia L. Smits; Dick H. W. Dekkers; Marcel A. Müller; Ronald Dijkman; Doreen Muth; Jeroen Demmers; Ali Moh Zaki; Ron A. M. Fouchier; Volker Thiel; Christian Drosten; Peter J. M. Rottier; Albert D. M. E. Osterhaus; Berend Jan Bosch; Bart L. Haagmans

Most human coronaviruses cause mild upper respiratory tract disease but may be associated with more severe pulmonary disease in immunocompromised individuals. However, SARS coronavirus caused severe lower respiratory disease with nearly 10% mortality and evidence of systemic spread. Recently, another coronavirus (human coronavirus-Erasmus Medical Center (hCoV-EMC)) was identified in patients with severe and sometimes lethal lower respiratory tract infection. Viral genome analysis revealed close relatedness to coronaviruses found in bats. Here we identify dipeptidyl peptidase 4 (DPP4; also known as CD26) as a functional receptor for hCoV-EMC. DPP4 specifically co-purified with the receptor-binding S1 domain of the hCoV-EMC spike protein from lysates of susceptible Huh-7 cells. Antibodies directed against DPP4 inhibited hCoV-EMC infection of primary human bronchial epithelial cells and Huh-7 cells. Expression of human and bat (Pipistrellus pipistrellus) DPP4 in non-susceptible COS-7 cells enabled infection by hCoV-EMC. The use of the evolutionarily conserved DPP4 protein from different species as a functional receptor provides clues about the host range potential of hCoV-EMC. In addition, it will contribute critically to our understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.


Journal of Virology | 2003

The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex

Berend Jan Bosch; Ruurd van der Zee; Cornelis A. M. de Haan; Peter J. M. Rottier

ABSTRACT Coronavirus entry is mediated by the viral spike (S) glycoprotein. The 180-kDa oligomeric S protein of the murine coronavirus mouse hepatitis virus strain A59 is posttranslationally cleaved into an S1 receptor binding unit and an S2 membrane fusion unit. The latter is thought to contain an internal fusion peptide and has two 4,3 hydrophobic (heptad) repeat regions designated HR1 and HR2. HR2 is located close to the membrane anchor, and HR1 is some 170 amino acids (aa) upstream of it. Heptad repeat (HR) regions are found in fusion proteins of many different viruses and form an important characteristic of class I viral fusion proteins. We investigated the role of these regions in coronavirus membrane fusion. Peptides HR1 (96 aa) and HR2 (39 aa), corresponding to the HR1 and HR2 regions, were produced in Escherichia coli. When mixed together, the two peptides were found to assemble into an extremely stable oligomeric complex. Both on their own and within the complex, the peptides were highly alpha helical. Electron microscopic analysis of the complex revealed a rod-like structure ∼14.5 nm in length. Limited proteolysis in combination with mass spectrometry indicated that HR1 and HR2 occur in the complex in an antiparallel fashion. In the native protein, such a conformation would bring the proposed fusion peptide, located in the N-terminal domain of HR1, and the transmembrane anchor into close proximity. Using biological assays, the HR2 peptide was shown to be a potent inhibitor of virus entry into the cell, as well as of cell-cell fusion. Both biochemical and functional data show that the coronavirus spike protein is a class I viral fusion protein.


Lancet Infectious Diseases | 2013

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study

Chantal Reusken; Bart L. Haagmans; Marcel A. Müller; Carlos Gutiérrez; Gert Jan Godeke; Benjamin Meyer; Doreen Muth; V. Stalin Raj; Laura de Vries; Victor Max Corman; Jan Felix Drexler; Saskia L. Smits; Yasmin E. El Tahir; Rita de Sousa; Janko van Beek; Norbert Nowotny; Kees van Maanen; Ezequiel Hidalgo-Hermoso; Berend Jan Bosch; Peter J. M. Rottier; Albert D. M. E. Osterhaus; Christian Gortázar-Schmidt; Christian Drosten; Marion Koopmans

Summary Background A new betacoronavirus—Middle East respiratory syndrome coronavirus (MERS-CoV)—has been identified in patients with severe acute respiratory infection. Although related viruses infect bats, molecular clock analyses have been unable to identify direct ancestors of MERS-CoV. Anecdotal exposure histories suggest that patients had been in contact with dromedary camels or goats. We investigated possible animal reservoirs of MERS-CoV by assessing specific serum antibodies in livestock. Methods We took sera from animals in the Middle East (Oman) and from elsewhere (Spain, Netherlands, Chile). Cattle (n=80), sheep (n=40), goats (n=40), dromedary camels (n=155), and various other camelid species (n=34) were tested for specific serum IgG by protein microarray using the receptor-binding S1 subunits of spike proteins of MERS-CoV, severe acute respiratory syndrome coronavirus, and human coronavirus OC43. Results were confirmed by virus neutralisation tests for MERS-CoV and bovine coronavirus. Findings 50 of 50 (100%) sera from Omani camels and 15 of 105 (14%) from Spanish camels had protein-specific antibodies against MERS-CoV spike. Sera from European sheep, goats, cattle, and other camelids had no such antibodies. MERS-CoV neutralising antibody titres varied between 1/320 and 1/2560 for the Omani camel sera and between 1/20 and 1/320 for the Spanish camel sera. There was no evidence for cross-neutralisation by bovine coronavirus antibodies. Interpretation MERS-CoV or a related virus has infected camel populations. Both titres and seroprevalences in sera from different locations in Oman suggest widespread infection. Funding European Union, European Centre For Disease Prevention and Control, Deutsche Forschungsgemeinschaft.


Emerging Infectious Diseases | 2014

Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013.

Ziad A. Memish; Matt Cotten; Benjamin Meyer; Simon J. Watson; Abdullah J. Alsahafi; Abdullah A. Al Rabeeah; Victor Max Corman; Andrea Sieberg; Hatem Q. Makhdoom; Abdullah Assiri; Malaki Al Masri; Souhaib Aldabbagh; Berend Jan Bosch; Martin Beer; Marcel A. Müller; Paul Kellam; Christian Drosten

We investigated a case of human infection with Middle East respiratory syndrome coronavirus (MERS-CoV) after exposure to infected camels. Analysis of the whole human-derived virus and 15% of the camel-derived virus sequence yielded nucleotide polymorphism signatures suggestive of cross-species transmission. Camels may act as a direct source of human MERS-CoV infection.


Emerging Infectious Diseases | 2014

Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013.

Benjamin H Meyer; Marcel A. Müller; Victor Max Corman; Chantal Reusken; Daniel Ritz; Gert-Jan Godeke; Erik Lattwein; Stephan Kallies; Artem Siemens; Janko van Beek; Jan Felix Drexler; Doreen Muth; Berend Jan Bosch; Ulrich Wernery; Marion Koopmans; Renate Wernery; Christian Drosten

Camels were infected with this virus >10 years before the first human cases.


Journal of Biological Chemistry | 2006

SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells

I-Chueh Huang; Berend Jan Bosch; Fang Li; Wenhui Li; Kyoung Hoa Lee; Sorina Ghiran; Natalya Vasilieva; Terence S. Dermody; Stephen C. Harrison; Philip R. Dormitzer; Michael Farzan; Peter J. M. Rottier; Hyeryun Choe

Viruses require specific cellular receptors to infect their target cells. Angiotensin-converting enzyme 2 (ACE2) is a cellular receptor for two divergent coronaviruses, SARS coronavirus (SARS-CoV) and human coronavirus NL63 (HCoV-NL63). In addition to hostcell receptors, lysosomal cysteine proteases are required for productive infection by some viruses. Here we show that SARS-CoV, but not HCoV-NL63, utilizes the enzymatic activity of the cysteine protease cathepsin L to infect ACE2-expressing cells. Inhibitors of cathepsin L blocked infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike (S) protein but not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein. Expression of exogenous cathepsin L substantially enhanced infection mediated by the SARS-CoV S protein and by filovirus GP proteins but not by the HCoV-NL63 S protein or the vesicular stomatitis virus G protein. Finally, an inhibitor of endosomal acidification had substantially less effect on infection mediated by the HCoV-NL63 S protein than on that mediated by the SARS-CoV S protein. Our data indicate that two coronaviruses that utilize a common receptor nonetheless enter cells through distinct mechanisms.


The New England Journal of Medicine | 2014

Transmission of MERS-coronavirus in household contacts

Christian Drosten; Benjamin Meyer; Marcel A. Müller; Victor Max Corman; Malak Almasri; Raheela Hossain; Hosam Madani; Andrea Sieberg; Berend Jan Bosch; Erik Lattwein; Raafat F. Alhakeem; Abdullah Assiri; Waleed H. Hajomar; Ali Albarrak; Jaffar A. Al-Tawfiq; Alimuddin Zumla; Ziad A. Memish

BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.


Emerging Infectious Diseases | 2014

Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992–2013

Victor Max Corman; Joerg Jores; Benjamin H Meyer; Mario Younan; Anne Liljander; Mohammed Y. Said; Ilona Gluecks; Erik Lattwein; Berend Jan Bosch; Jan Felix Drexler; Set Bornstein; Christian Drosten; Marcel A. Müller

Dromedary camels are a putative source for human infections with Middle East respiratory syndrome coronavirus. We showed that camels sampled in different regions in Kenya during 1992–2013 have antibodies against this virus. High densities of camel populations correlated with increased seropositivity and might be a factor in predicting long-term virus maintenance.


Nanomedicine: Nanotechnology, Biology and Medicine | 2012

Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles

Esther N.M. Nolte-'t Hoen; Els J. van der Vlist; Marian Aalberts; Hendrik C.H. Mertens; Berend Jan Bosch; Willem Bartelink; Enrico Mastrobattista; Ethlinn V.B. van Gaal; Willem Stoorvogel; Ger J. A. Arkesteijn; Marca H. M. Wauben

Abstract Nanosized cell-derived membrane vesicles are increasingly recognized as therapeutic vehicles and high-potential biomarkers for several diseases. Currently available methods allow bulk analysis of vesicles but are not suited for accurate quantification and fail to reveal phenotypic heterogeneity in membrane vesicle populations. For such analyses, single vesicle-based, multiparameter, high-throughput methods are needed. We developed a fluorescence-based, high-resolution flow cytometric method for quantitative and qualitative analysis of nanosized membrane vesicles. Proof of principle was obtained by single-particle analysis of virions and liposomes. Further validation was obtained by quantification of cell-derived nanosized membrane vesicles from cell cultures and body fluids. An important aspect was that the technology was extended to detect specific proteins on individual vesicles. This allowed identification of exosome subsets and phenotyping of individual exosomes produced by dendritic cells (DCs) undergoing different modes of activation. The described technology allows quantitative, multiparameter, and high-throughput analysis of a wide variety of nanosized particles and has broad applications. From the Clinical Editor The authors developed a fluorescence-based, high-resolution flow cytometric method for quantitative and qualitative analysis of nanosized cell-derived membrane vesicles that are increasingly recognized both as therapeutic vehicles and high-potential biomarkers for several diseases. A high throughput, easily available, and sensitive detection method such as the one discussed here is a critically important prerequisite for further refinements of this technology.


Eurosurveillance | 2013

Middle East Respiratory Syndrome coronavirus (MERS- CoV) serology in major livestock species in an affected region in Jordan, June to September 2013

Chantal Reusken; Mustafa M. Ababneh; V S Raj; Benjamin Meyer; Abdulhakeem Eljarah; S Abutarbush; Gert-Jan Godeke; Theo M. Bestebroer; I Zutt; Marcel A. Müller; Berend Jan Bosch; Peter J. M. Rottier; Albert D. M. E. Osterhaus; Christian Drosten; Bart L. Haagmans; Marion Koopmans

Between June and September 2013, sera from 11 dromedary camels, 150 goats, 126 sheep and 91 cows were collected in Jordan, where the first human Middle-East respiratory syndrome (MERS) cluster appeared in 2012. All sera were tested for MERS-coronavirus (MERS-CoV) specific antibodies by protein microarray with confirmation by virus neutralisation. Neutralising antibodies were found in all camel sera while sera from goats and cattle tested negative. Although six sheep sera reacted with MERS-CoV antigen, neutralising antibodies were not detected.

Collaboration


Dive into the Berend Jan Bosch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bart L. Haagmans

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

V. Stalin Raj

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marion Koopmans

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge